Biotech has delivered one of its strongest rallies in years, fueled by a resurgence in M&A activity, improving sentiment and continued innovation. But as valuations rise and competition intensifies, investors are becoming increasingly selective. RBC's biotech analysts explore the key drivers behind the rally, the outlook for M&A, the growing role of China and what could determine whether the sector sustains momentum through the second half of the year.

Key Points

  • M&A activity, improving regulatory sentiment and strong clinical data have helped drive a significant re-rating across biotech.
  • Higher valuations have boosted investor confidence but may leave less room for error in the second half.
  • Innovation continues to underpin long-term growth opportunities, although competition is increasing.
  • China's growing role in drug development is reshaping competitive dynamics and business development strategies.
  • Investors are becoming increasingly selective, with a greater focus on company-specific catalysts and fundamentals.


Chapter Markers

What's driving biotech's rally? [00:52)

  • Brian Abrahams explores the key factors behind biotech's resurgence..


Why selectivity matters more now [2:30]

  • Rising valuations have strengthened confidence across biotech, but investors may need to become more discerning about where they allocate capital in the second half.


The outlook for biotech M&A [4:02]

  • M&A remains a leading catalyst for biotech investors, with deal activity continuing to shape sentiment and sector performance.


What the biotech investor survey revealed [7:11]

  • Lisa Walter discusses investor positioning, valuation expectations and why enthusiasm remains constructive despite a more neutral stance following the rally.


Innovation, drug launches and competitive advantage [11:02]

  • Leonid Timashev explores how innovation, commercial execution and emerging modalities are shaping competitive advantage in biotech, and why successful launches remain critical to long-term value creation.


China's growing influence in biotech [17:44]

  • China's emergence as a leading source of innovation and business development activity is reshaping competitive dynamics across the biotech sector.


What could drive the second half? [20:15]

  • RBC analysts discuss the factors most likely to determine whether biotech can sustain its momentum.


Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör RBC Capital Markets. Innehållet i podden är skapat av RBC Capital Markets och inte av, eller tillsammans med, Poddtoppen.